Drug Profile
Dolutegravir/emtricitabine/tenofovir alafenamide - Viatris
Latest Information Update: 25 Feb 2022
Price :
$50
*
At a glance
- Originator Mylan
- Developer Viatris Inc
- Class 3-ring heterocyclic compounds; Adenine nucleotides; Amides; Antiretrovirals; Deoxyribonucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections